Exact Sciences Highlights CMS Advisory Panel's Unanimous Vote to Maintain Medicare Reimbursement Rate for Cologuard®

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) Advisory Panel on Clinical Diagnostic Laboratory Tests voted unanimously to maintain Medicare's current crosswalk pricing ($492.72) for Cologuard. The 11-0 vote, including one abstention, came after the Clinical Lab Fee Schedule's July 16, 2015 public meeting. Exact Sciences' Chairman and CEO Kevin Conroy presented a proposal at the July 16th meeting to crosswalk Cologuard from its current G-code to a CPT code. Following today's vote, Conroy issued this statement:

Read More

Topics: Exact Sciences News